Linagliptin Intas

Linagliptin, the active ingredient in Linagliptin Intas, is a DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of blood glucose in adults with type 2 diabetes mellitus, helping to improve glycaemic control when used as part of a comprehensive diabetes treatment plan. It works by selectively inhibiting the dipeptidyl peptidase‑4 enzyme, thereby increasing endogenous incretin levels and promoting glucose‑dependent insulin secretion while reducing glucagon release.

GNH USA supplies Linagliptin Intas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is used in the oral antidiabetic drug class to improve glycaemic control in type 2 diabetes.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose as an adjunct to diet and exercise. Adjunct therapy with metformin: provides additional glucose‑lowering effect when metformin alone does not achieve target levels. Monotherapy in patients intolerant to other agents: offers an oral option for glycaemic control when other oral antidiabetics are unsuitable.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate headache. - Upper respiratory tract infection: symptoms of cough, sore throat, or congestion. - Dizziness: occasional light‑headed sensation. - Gastrointestinal discomfort: mild nausea or abdominal pain. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain, nausea, and vomiting requiring immediate medical attention. - Severe hypersensitivity reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Acute renal failure: sudden decrease in kidney function.

Linagliptin should be used with clinical vigilance in the following situations: - Renal function monitoring: assess renal status before initiation and periodically thereafter. - Hepatic function assessment: evaluate liver enzymes prior to treatment and monitor if clinically indicated. - Pancreatitis risk: discontinue if signs of pancreatitis develop. - Elderly patients: start at the lowest effective dose and monitor for adverse reactions. - Concomitant hypoglycaemic agents: adjust dose of sulfonylureas or insulin to avoid hypoglycaemia. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with several drug classes, requiring attention to dosing and monitoring. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness. - Insulin or sulfonylureas: combined use can heighten risk of hypoglycaemia. Moderate Interactions (Monitor Closely):\n- Diuretics: may affect glucose control and electrolyte balance. - NSAIDs: can impact renal function, especially in patients with pre‑existing kidney disease. - Antihypertensives: monitor blood pressure as improved glycaemic control may alter hemodynamics.